the paola-1 study: olaparib and bevacizumab for ovarian cancer
Published 5 years ago • 1.3K plays • Length 2:27Download video MP4
Download video MP3
Similar videos
-
9:49
paola-1 phase 3 data: olaparib plus bevacizumab maintenance for advanced ovarian cancer
-
1:13
final os results from paola-1 evaluating 1l maintenance olaparib plus bevacizumab
-
3:37
selecting patients to be treated with maintenance olaparib in the paola-1 trial
-
3:58
the potential of parp inhibitors in ovarian cancer: paola-1, prima & velia
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
4:14
paola-1 study surgical subset for ovarian cancer
-
3:28
implications of paola-1 in advanced ovarian cancer
-
3:40
paola-1: combination maintenance therapy in ovarian cancer
-
3:42
parp maintenance bevacizumab in ovarian cancer
-
6:56
#esmo19: positive trial for ovarian cancer: paola-1/engot-ov25
-
4:23
comment: parp inhibitor olaparib plus bevacizumab in women with ovarian cancer
-
7:56
maintenance therapy in ovarian cancer
-
6:01
olaparib and bevacizumab: on the horizon for treating ovarian cancer
-
3:58
solo-1: practice changing data on olaparib for ovarian cancer
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
3:47
gog-0218: which patients with ovarian cancer experience highest benefit from 1l bevacizumab?
-
3:11
the avanova study: niraparib and bevacizumab for ovarian cancer
-
1:57
7-year os from solo1: sustained benefit with maintenance olaparib
-
7:16
the paola trial: layering parpi onto antiangiogenic therapy